Healthcare
ICON Public Limited Company(ICLR)
Live Price
Offline$146.00
+1.91% today
1Y Change
+0.06%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $9.04B
- Revenue Growth
- +2.0%
- EPS Growth
- +28.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ICON Public Limited Company (ICLR) is a Healthcare stock with a market cap of $9.04B and listed on NASDAQ. The stock last traded around $146.00 and up 0.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +2.0%, EPS growth of +28.7%, a dividend yield of 0.0%. What stands out right now is revenue +2.0%, EPS +28.7%, free cash flow +9.6% with operating margin 12.2% and ROIC 6.9%. Valuation is more restrained than many high-expectation growth names at P/E 15.3 and price/sales 1.1. Stock Foundry combines ICLR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.0% vs +7.6% peer median
Operating Margin
Below sector median
+12.2% vs +19.4% peer median
P/E
Below sector median
15.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2.0% and EPS at +28.7%, with operating margin around 12.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +1.9% | +6.9% | +17.8% |
2026 Apr 1, 2026 | โ | +2.5% | -4.2% | +6.2% |
2025 Oct 22, 2025 | +0.9% | -6.5% | -13.8% | -17.5% |
Benchmark Edge
ICLR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ICLR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ICLR Max Drawdown
-60.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ICLR and SPY.
Company Overview
ICON Public Limited Company
NASDAQ Global Select
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
- Leadership
- Barry Balfe
- IPO Date
- May 15, 1998
- Employees
- 41.3k
- Street Address
- South County Business Park
- Mailing
- Dublin, 18
- Region
- Dublin, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 291 2000
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.3
- EV/EBITDA
- 10.3
- Price/Sales
- 1.1
- Price/Book
- 1.0
Growth
- Revenue
- +2.0%
- EPS
- +28.7%
- Free Cash Flow
- +9.6%
Profitability
- Gross Margin
- 26.9%
- Operating Margin
- 12.2%
- Net Margin
- 7.4%
- ROE
- 6.3%
- ROIC
- 6.9%
Balance Sheet
- Debt/Equity
- 0.38
- Current Ratio
- 1.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.